Aliskiren: the first direct renin inhibitor for hypertension (Q37000071)

17 August 2017

1 reference

title

Aliskiren: the first direct renin inhibitor for hypertension (English)

1 reference

17 August 2017

main subject

arterial hypertension

0 references

author name string

Anton H van den Meiracker

series ordinal

1

1 reference

17 August 2017

A H Jan Danser

series ordinal

2

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Current cardiology reports

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

470-476

1 reference

Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction

17 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02938391

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02938391

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02938391

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

21 January 2018

1 reference

12 December 2020

Local renin-angiotensin systems: the unanswered questions

1 reference

12 December 2020

Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition

1 reference

12 December 2020

Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations

1 reference

12 December 2020

Renin inhibition: what are the therapeutic opportunities?

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

1 reference

12 December 2020

An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria

1 reference

12 December 2020

Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy

1 reference

12 December 2020

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

1 reference

12 December 2020

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

12 December 2020

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

12 December 2020

Intrarenal angiotensin II: interstitial and cellular levels and site of production

1 reference

12 December 2020

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

12 December 2020

Angiotensin converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of the isolated perfused rat heart

1 reference

12 December 2020

Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding

1 reference

12 December 2020

Transendothelial transport of renin-angiotensin system components

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

12 December 2020

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

12 December 2020

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

12 December 2020

Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans

1 reference

12 December 2020

Renin, prorenin and the putative (pro)renin receptor

1 reference

12 December 2020

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

12 December 2020

ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?

1 reference

12 December 2020

Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure

1 reference

12 December 2020

Prorenin Induces Intracellular Signaling in Cardiomyocytes Independently of Angiotensin II

1 reference

12 December 2020

Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness.

1 reference

12 December 2020

Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries

1 reference

12 December 2020

Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.

1 reference

12 December 2020

Angiotensin II production and distribution in the kidney: I. A kinetic model

1 reference

12 December 2020

AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation

1 reference

12 December 2020

Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis

1 reference

12 December 2020

Plasma prorenin in normal, hypertensive, and anephric subjects and its effect on renin measurements

1 reference

12 December 2020

Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II.

1 reference

12 December 2020

Vasoconstriction is determined by interstitial rather than circulating angiotensin II

1 reference

12 December 2020

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

12 December 2020

Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice

1 reference

12 December 2020

Elevated blood pressure and heart rate in human renin receptor transgenic rats.

1 reference

12 December 2020

Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats

1 reference

12 December 2020

Angiotensin II production and distribution in the kidney--II. Model-based analysis of experimental data

1 reference

12 December 2020

Nephrectomy, converting enzyme inhibition, and angiotensin peptides

1 reference

12 December 2020

High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin

1 reference

12 December 2020

Adrenal angiotensin: origin and site of generation

1 reference

12 December 2020

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

1 reference

12 December 2020

Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02938391

1 reference

release_i6jdlq4grvdlnkthtt57njoqeu

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i6jdlq4grvdlnkthtt57njoqeu

24 November 2022

mapped directly with Wikidata item

1 reference